Literature DB >> 8462096

Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans.

M Noguchi1, H Yi, H M Rosenblatt, A H Filipovich, S Adelstein, W S Modi, O W McBride, W J Leonard.   

Abstract

The interleukin-2 (IL-2) receptor gamma chain (IL-2R gamma) is a component of high and intermediate affinity IL-2 receptors that is required to achieve full ligand binding affinity and internalization. We have localized the IL-2R gamma gene to human chromosome Xq13. Genetic linkage analysis indicates that the IL-2R gamma gene and the locus for X-linked severe combined immunodeficiency (XSCID) appear to be at the same position. Moreover, we demonstrate that each of three unrelated patients with XSCID has a different mutation in his IL-2R gamma gene resulting in a different premature stop codon and predicted C-terminal truncation. These data establish that XSCID is associated with mutations of the IL-2R gamma gene product. Since XSCID is characterized by absent or markedly reduced numbers of T cells, our findings imply that IL-2R gamma plays a vital role in thymic maturation of T cells. These results also have important implications for prenatal and postnatal diagnosis, carrier female detection, and gene therapy for XSCID.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462096     DOI: 10.1016/0092-8674(93)90167-o

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  304 in total

Review 1.  Severe combined immunodeficiency--molecular pathogenesis and diagnosis.

Authors:  H B Gaspar; K C Gilmour; A M Jones
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

Review 2.  Primary T-lymphocyte immunodeficiencies.

Authors:  A Fischer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

3.  Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor.

Authors:  P Bousso; V Wahn; I Douagi; G Horneff; C Pannetier; F Le Deist; F Zepp; T Niehues; P Kourilsky; A Fischer; G de Saint Basile
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 4.  Severe combined immunodeficiencies (SCID).

Authors:  A Fischer
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 5.  Hematopoietic stem cell transplantation for severe combined immune deficiency.

Authors:  K I Weinberg; N Kapoor; A J Shah; G M Crooks; D B Kohn; R Parkman
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

Review 6.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

7.  Differential requirement of the cytoplasmic subregions of gamma c chain in T cell development and function.

Authors:  S Tsujino; J P Di Santo; A Takaoka; T L McKernan; S Noguchi; C Taya; H Yonekawa; T Saito; T Taniguchi; H Fujii
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

8.  A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.

Authors:  Sheng Zhou; Disha Mody; Suk See DeRavin; Julia Hauer; Taihe Lu; Zhijun Ma; Salima Hacein-Bey Abina; John T Gray; Michael R Greene; Marina Cavazzana-Calvo; Harry L Malech; Brian P Sorrentino
Journal:  Blood       Date:  2010-05-10       Impact factor: 22.113

9.  Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment.

Authors:  Federica Cattaneo; Mike Recher; Stefania Masneri; Sachin N Baxi; Claudia Fiorini; Francesca Antonelli; Christian A Wysocki; Jose G Calderon; Hermann Eibel; Angela R Smith; Francisco A Bonilla; Erdyni Tsitsikov; Silvia Giliani; Luigi D Notarangelo; Sung-Yun Pai
Journal:  J Allergy Clin Immunol       Date:  2013-02-04       Impact factor: 10.793

10.  IL-21 mediates suppressive effects via its induction of IL-10.

Authors:  Rosanne Spolski; Hyoung-Pyo Kim; Wei Zhu; David E Levy; Warren J Leonard
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.